Mantle cell lymphoma treatment offers options if patients relapse after CAR T-cell therapy, from bispecific antibodies, antibody drug conjugates, and other emerging therapies.

The patients receiving AHSCT had 5-year LFS of 46.3% and OS of 53.3%, which were better outcomes than those of the MRC UKALL XII/ECOG E2993 trial conducted from 2006 to 2010.

Discover the current pipeline candidates advancing through the clinic for the treatment of sickle cell disease.

CRISPR construct to genetically ablate the GABA transporter GAT3 in the mouse visual cortex, with effects on population-level neuronal activity. This work is important, as it sheds light on how GAT3 ...

This cell line is capable of stably expressing Moloney murine leukemia virus gag-pol proteins and the GALV envelope (16, 17). Following the two-step stable transfection of this cell line with the ...

AAV producer cell lines offer process benefits First, stable AAV producer cell lines simplify production by eliminating the need for transient transfection and helper virus infection.

Every Patient Is Unique and Deserves the Best: The Present and Future Treatment Landscape of Uncommon Epidermal Growth Factor Receptor Mutations in Non–Small Cell Lung Cancer. If you have the ...

Legend Biotech's Carvykti shows strong efficacy in multiple myeloma as U.S.-based manufacturing shields it from tariffs and global regulatory risks.

The stable nanoparticles were then complexed with enhanced cyanine fluorescence protein plasmid (pECFP) and their transfection efficiencies in Hela cell line were studied. It was found that gold ...